Literature DB >> 11408337

Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome.

M A Willemsen1, L IJlst, P M Steijlen, J J Rotteveel, J G de Jong, P H van Domburg, E Mayatepek, F J Gabreëls, R J Wanders.   

Abstract

Sjögren-Larsson syndrome (SLS) is an autosomal recessively inherited neurocutaneous disorder caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH). We report the clinical characteristics and the results of molecular studies in 19 SLS patients. Patients 1-17 show the classical triad of severe clinical abnormalities including ichthyosis, mental retardation and spasticity. Most patients were born preterm, and all patients exhibit ocular abnormalities and pruritus. Electro-encephalography shows a slow background activity, without other abnormalities. MRI of the brain shows an arrest of myelination, periventricular signal abnormalities of white matter and mild ventricular enlargement. Cerebral (1)H-MR spectroscopy reveals a characteristic, abnormal lipid peak. The degree of white matter abnormality in the MRIs and the height of the lipid peak in (1)H-MR spectra do not correlate with the severity of the neurological signs. The clinical presentation and the clinical course is strikingly similar in these patients. Patient 18 shows a mild phenotype that essentially contains the same, but less severe, clinical features. Patient 19 exhibits the typical, but very mild, dermatological and ocular abnormalities, without any clinical neurological involvement. The diagnosis of SLS was confirmed by demonstration of the enzyme defect in cultured skin fibroblasts. Furthermore, as might be predicted from the essential role of FALDH in leucotriene B(4) (LTB(4)) metabolism, elevated urinary concentrations of LTB(4) and 20-OH-LTB(4) were found in all patients studied. Molecular studies of the FALDH gene revealed eight different mutations, including three new ones: a large 26-base pair deletion (21-46del), a missense mutation (80C-->T) and an insertion mutation (487-488insA). The vast majority of SLS patients seem to be severely affected independent of their genotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408337     DOI: 10.1093/brain/124.7.1426

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  24 in total

1.  A novel assay for the prenatal diagnosis of Sjögren-Larsson syndrome.

Authors:  D M van den Brink; J M van Miert; R J A Wanders
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.

Authors:  F Lamari; F Mochel; F Sedel; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  2012-07-20       Impact factor: 4.982

3.  An overview of inborn errors of complex lipid biosynthesis and remodelling.

Authors:  Foudil Lamari; Fanny Mochel; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2014-09-20       Impact factor: 4.982

4.  Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Hasnaa M Elbendary; Sherif F Abdel-Ghafar; Karima Rafaat; Heba Hosny; Marian Girgis; Ghada M H Abdel-Salam; Maha S Zaki
Journal:  J Hum Genet       Date:  2019-07-05       Impact factor: 3.172

5.  Novel mutation in Sjogren-Larsson syndrome is associated with divergent neurologic phenotypes.

Authors:  Kathleen Davis; Kenton R Holden; Dana S'Aulis; Claudia Amador; M Gisele Matheus; William B Rizzo
Journal:  J Child Neurol       Date:  2012-10-03       Impact factor: 1.987

Review 6.  Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: a diagnostic approach.

Authors:  F Sedel; B Fontaine; J M Saudubray; O Lyon-Caen
Journal:  J Inherit Metab Dis       Date:  2007-10-22       Impact factor: 4.982

7.  Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system.

Authors:  Ujjawal Roy; Urmila Das; Alak Pandit; Anjan Debnath
Journal:  BMJ Case Rep       Date:  2016-04-19

8.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy.

Authors:  Michèl A A P Willemsen; Marinette Van Der Graaf; Marjo S Van Der Knaap; Arend Heerschap; Peter H M F Van Domburg; Fons J M Gabreëls; Jan J Rotteveel
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

9.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

10.  Phenotypic variability among adult siblings with Sjögren-Larsson syndrome.

Authors:  Alexander Lossos; Moona Khoury; William B Rizzo; John M Gomori; Eyal Banin; Abraham Zlotogorski; Saleh Jaber; Oded Abramsky; Zohar Argov; Hanna Rosenmann
Journal:  Arch Neurol       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.